# Fonds Vives II (University of Louvain, UCL)

> Fonds Vives II (University of Louvain, UCL) is a VC fund backing Biotechnology and Health Care. See 5 investments, check sizes, portfolio. Updated Aug 2026.

- Type: VC Fund
- Total investments: 5
- Last investment: Dec 2021
- Lead investor: 0%
- Last updated: Aug 2026

Fonds Vives II (University of Louvain, UCL) is a VC fund focused on Biotechnology and Health Care. Fonds Vives II (University of Louvain, UCL)

## Round sizes

| Stage | Round size |
| --- | --- |
| Series A | $9.9M–$14M |
| Series B | $6.6M–$75M |

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Biotechnology | 3 | 60% |
| Health Care | 2 | 40% |
| Medical | 1 | 20% |
| Wellness | 1 | 20% |
| Biopharma | 1 | 20% |

10 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series A | 2 | 40% |
| Series B | 2 | 40% |
| Seed | 1 | 20% |

### Country

| Country | Investments | Share |
| --- | --- | --- |
| Belgium | 3 | 60% |
| United States | 1 | 20% |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Sunrise | Sunrise aims to bring simple answers to millions of people suffering from sleep disorders.We have developed a 3-gram sensor to diagnose sleep with gold standard quality. The technology offers a revolutionary new way to measure brain commands at night, with published clinical results never seen before. Studies demonstrate Sunrise is as accurate asin-lab sleep studies, at a fraction of the cost.Affecting one in three people, sleep disorders are extremely common. Sleep apnea is the most prevalent disease with almost 1 billion persons concerned. This condition leads to great body damage over time and yet remains undiagnosed in 80% of the cases.Patients, caregiver and insurers stand to benefit greatly from a solution to current highly cumbersome, expensive and time-consuming diagnostics systems. | $7.3M | Seed | Dec 15, 2021 |  |
| Virovet | ViroVet is a pioneering company dedicated to the development of disruptive and innovative technologies for the control of viral diseases in livestock, with antiviral drugs for respiratory disease complexes and innovative vaccines for viral infections in swine leading the pipeline. The livestock industry is a 100+ billion-euro industry. Viraldiseases cost producers billions every year in losses and threaten the world supply of animal protein.The strategy of ViroVet is to provide novel solutions to be used alone or in combination with vaccines and biosecurity measures in order to provide livestock producers, national governments and international organizations with a multi-faceted arsenal of virus control weapons against endemic and epizootic viral diseases.It is clear that with the growing world population there is an increased demand for more protein-rich diets. With the increasing density of the livestock industry, the intensifying global trade and climate changes, there is an ever increased risk for the global spread of viral diseases, severely damaging livestock industry.ViroVet has already enlisted the support of a number of key opinion leaders (KOLs) in livestock medicine confirming the extensive market for antiviral drugs and novel vaccines addressing the challenges of spreading viral diseases. KOLs feel that ViroVet’s products have the potential to reduce the use of antibiotics and revolutionize the livestock industry worldwide. | $6.6M | Series B | May 28, 2020 |  |
| ITeos Therapeutics | ITeos Therapeutics is a private biotechnology company targeting the metabolism of the tumor microenvironment to develop small molecule immunomodulators for cancer treatments. iTeos is building its activities upon the unparalleled expertise of the Ludwig Cancer Research (LICR) – a world-class Research Institute in the fields of tumor immunology,therapeutic cancer vaccines, cancer biology, and translational medicine in cancer.iTeos endeavors to develop small molecules designed to target the tumor microenvironment by inhibiting cancer-induced immune suppression. Targeting such resistance mechanisms will enhance the clinical efficacy of both standards of care treatments as well as the newer immunomodulatory therapies based on the blockade of immune checkpoints (e.g. anti-CTLA4, anti-PD1, and anti-PDL1 antibodies). | $75M | Series B | Jun 20, 2018 |  |
| A-Mansia Biotech | A-Mansia Biotech is a developer of products based on the properties of the Akkermansia muciniphila (A. muciniphila) bacterium. The company's nutritional supplement based on a gut bacterium called Akkermansia, the population of microorganisms housed in the gastrointestinal tract. A. muciniphila is located in the mucus layer covering theintestinal epithelium, which allows the bacterium to establish a close cross-talk with the host. | $14.3M | Series A | Apr 27, 2018 |  |
| ITeos Therapeutics | ITeos Therapeutics is a private biotechnology company targeting the metabolism of the tumor microenvironment to develop small molecule immunomodulators for cancer treatments. iTeos is building its activities upon the unparalleled expertise of the Ludwig Cancer Research (LICR) – a world-class Research Institute in the fields of tumor immunology,therapeutic cancer vaccines, cancer biology, and translational medicine in cancer.iTeos endeavors to develop small molecules designed to target the tumor microenvironment by inhibiting cancer-induced immune suppression. Targeting such resistance mechanisms will enhance the clinical efficacy of both standards of care treatments as well as the newer immunomodulatory therapies based on the blockade of immune checkpoints (e.g. anti-CTLA4, anti-PD1, and anti-PDL1 antibodies). | $9.9M | Series A | May 03, 2012 |  |

5 of 5 investments shown.

## Co-investors
- [Fund+](https://shizune.co/investors/profile/fund) — VC Fund, 2 deals together
- [Seventure Partners](https://shizune.co/investors/profile/seventure-partners) — VC Fund, 2 deals together
- [SFPI-FPIM](https://shizune.co/investors/profile/sfpi-fpim) — VC Fund, 2 deals together
- [S.R.I.W.](https://shizune.co/investors/profile/s-r-i-w) — VC Fund, 2 deals together
- [6 Dimensions Capital](https://shizune.co/investors/profile/6-dimensions-capital) — VC Fund, 1 deal together
- [Agri Investment Fund](https://shizune.co/investors/profile/agri-investment-fund) — VC Fund, 1 deal together

## Similar investors

### Similar industry
- [Right Side Capital Management](https://shizune.co/investors/profile/right-side-capital-management) — VC Fund
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [SOSV](https://shizune.co/investors/profile/sosv) — VC Fund

### Similar stage
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund

### Similar country
- [PMV](https://shizune.co/investors/profile/pmv-eu) — VC Fund
- [Limburgse Reconversie Maatschappij](https://shizune.co/investors/profile/limburgse-reconversie-maatschappij) — VC Fund
- [Qbic Fund](https://shizune.co/investors/profile/qbic-fund) — VC Fund

## Featured in investor lists
- [Health Care Investors in Belgium](https://shizune.co/investors/health-care-investors-belgium)
- [Health Care VC Funds in Belgium](https://shizune.co/investors/health-care-vc-funds-belgium)
- [Wellness Investors in Belgium](https://shizune.co/investors/wellness-investors-belgium)
- [Wellness VC Funds in Belgium](https://shizune.co/investors/wellness-vc-funds-belgium)
- [Community VC Funds in Belgium](https://shizune.co/investors/community-vc-funds-belgium)
- [Life Science Investors in Belgium](https://shizune.co/investors/life-science-investors-belgium)

## FAQ

### What does Fonds Vives II (University of Louvain, UCL) invest in?

Fonds Vives II (University of Louvain, UCL) invests primarily in Biotechnology, Health Care and Medical startups, most often at Series A and Series B stage. Most of the 5 investments tracked by Shizune back companies in Belgium. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### What is Fonds Vives II (University of Louvain, UCL)'s check size?

Fonds Vives II (University of Louvain, UCL) typically joins rounds of $9.9M–$14M at Series A and $6.6M–$75M at Series B. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds Fonds Vives II (University of Louvain, UCL) participates in.

### When did Fonds Vives II (University of Louvain, UCL) last invest?

The most recent investment recorded for Fonds Vives II (University of Louvain, UCL) closed in Dec 2021. Shizune tracks 5 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co